News round-up for 8-12 January by DDW Digital Content Editor Diana Spencer.
This week has seen a number of significant discoveries by researchers in academic institutions, in some cases in partnership with industry, emphasising the important role universities play in early-stage drug discovery. Perhaps most importantly, a new antibiotic was found that targets a Gram-negative pathogen, mRNA was used as an effective therapy for a rare liver disease, and a common immune cell was found to attack cancer.
The top stories:
A novel antibiotic class targeting a major global pathogen and threat to human health has been discovered by scientists from Roche and Harvard University (Cambridge, MA, US).
New understanding of a gene that is linked to some forms of dementia and other age-related diseases gives scientists fresh hope that action can be taken against these diseases long before the onset of symptoms.
Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people.
Researchers in the US have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer.
A study has revealed that Covid-19 vaccines are effective in preventing long Covid, but the BioNTech/Pfizer vaccine provided better protection than ChAdOx1, developed by Oxford University/AstraZeneca.